|
|
|
VGX International Inc.
Added to the KOSPI 200 Index
|
| Blue
Bell, PA – June 15, 2007 – |
|
VGX Pharmaceuticals Inc. announced today that its
publicly-traded Korean affiliate, VGX International Inc. (Korean Stock
Exchange: Stock Ticker No. 011000), has been added to the prestigious
KOSPI 200 Index. The KOSPI 200 Index, established in January 1990, is
a capitalization-weighted index of 200 Korean stocks that make up 93%
of the total market value of the Korea Stock Exchange.
The KOSPI 200 Index includes several well-known global companies such
as Samsung Electronics, POSCO, and Hyundai Motor Co. VGX International
joins a handful of major Korean pharmaceutical companies already in the
index including Yuhan Pharma, Dong-A Pharma, CKD Pharma, and LG Life Sciences.
VGX International and nine other newly added companies are replacing ten
out-going companies as a part of Korean Stock Exchange’s efforts
to reposition the index to better reflect the current market environment.
Since November 2005, VGX Pharmaceuticals has been the controlling shareholder
of VGX International, which focuses on manufacturing and development of
pharmaceutical products. VGX Pharmaceuticals and VGX International are
currently co-developing VGX-1027, a novel drug compound for treating Type1
Diabetes, and the two companies are planning to co-develop several other
novel drug compounds including VGX-100 for Gastric Cancer.
Cautionary
Factors That May Affect Future Results - Materials in this
Web site contain information that includes or is based upon forward-looking
statements within the meaning of the Securities Litigation Reform
Act of 1995. Forward-looking statements relate to expectations or
forecasts of future events. You can identify these statements by the
fact that they do not relate strictly to historical or current facts.
They use words such as "anticipate," "estimate,"
"expect," "project," "intend," "plan,"
"believe," and other words and terms of similar meaning
in connection with a discussion of potential future events, circumstances
or future operating or financial performance. In particular, these
include statements relating to future actions, prospective products
or product approvals, future performance or results of current and
anticipated products, sales efforts, expenses, the outcome of contingencies
such as legal proceedings, and financial results. Any or all of our
forward-looking statements here or in other publications may turn
out to be wrong. They can be affected by inaccurate assumptions or
by known or unknown risks and uncertainties. Many such factors will
be important in determining our actual future results. Consequently,
no forward-looking statement can be guaranteed, and forward-looking
statements may be adversely affected by factors, including general
market conditions, competitive product development, product availability,
current and future branded and generic competition, federal and state
regulations and legislation, manufacturing issues, timing of the elimination
of trade buying, patent positions, litigations and investigations.
Our actual results may vary materially, and there are no guarantees
about the performance or valuation of VGX stock. It is also important
to read the disclosure notice contained in many of the individual
VGX documents available on this Web site as many contain important
information on such cautionary factors as of the date of the individual
document. We undertake no obligation to correct or update any forward-looking
statements, whether as a result of new information, future events
or otherwise. You are advised, however, to consult any further disclosures
we make on related subjects in our reports. |
About VGX
Pharmaceuticals
VGX VGX Pharmaceuticals is a biopharmaceutical company with small molecules
and biologics product candidates for the treatment of infectious diseases,
cancer and inflammatory diseases. The Company's clinical development programs
include PICTOVIR™ for HIV infection and VGX-410C for chronic HCV infection,
both of which are currently in Phase II clinical trials. In addition, VGX
is planning to initiate Phase I clinical studies for VGX-1027, its lead
compound for inflammatory diseases. VGX's research pipelines include new
generation of DNA vaccines and therapeutics as well as CELLECTRA™,
a proprietary DNA delivery device. The product candidates and technology
programs are protected by the Company's extensive global intellectual property
portfolio. More information about VGX can be found at www.vgxp.comat www.vgxp.com.
Company Contact:
Kevin W. Rassas
Senior Vice President
Tel. 267.440.4208
Fax 267.440.4242
E-mail: Rassas@vgxp.com
www.vgxp.com
|
